Skip to main content
. Author manuscript; available in PMC: 2014 Oct 1.
Published in final edited form as: Am J Surg Pathol. 2013 Oct;37(10):1592–1602. doi: 10.1097/PAS.0b013e31828f233d

Figure 2.

Figure 2

Serial sections of four different CRCs stained with hematoxylin and eosin (A,D,G,J), and IHC for BRAFV600E (B,E,H,K) and MLH1 (C,F,I,L). The tumor in A-B-C is MSS (positive staining was also seen for PMS2, MSH2 and MSH6) and BRAFV600E positive. This appears to represent a poor prognostic group. The tumour in D-E-F is BRAFV600E negative and MSS. The tumor illustrated in G-H-I shows negative staining for MLH1 and demonstrates MSI. It also demonstrates positive staining for BRAFV600E therefore LS is essentially excluded. The tumor illustrated in J-K-L demonstrates MSI and negative staining for BRAFV600E therefore in this instance formal genetic testing for LS is justified. As illustrated in panels B and H, positive staining for BRAFV600E is characterized by widespread cytoplasmic staining limited to tumor cells (Original magnifications 100X).